Hexatrione (Triamcinolone Hexacetonide)

Hexatrione is indicated for intra‑articular injection in several inflammatory joint disorders where rapid local control of inflammation is desired.

• Osteoarthritis of the knee or other large joints.
• Rheumatoid arthritis affecting a single joint.
• Juvenile idiopathic arthritis with persistent synovitis.
• Psoriatic arthritis or gouty arthritis when local therapy is preferred.
• Other refractory inflammatory joint disorders where systemic steroids are contraindicated.
• Post‑traumatic joint inflammation unresponsive to NSAIDs.
• Synovitis associated with hemophilic arthropathy.
• Inflammatory complications of joint prostheses that are not amenable to surgical revision.
• Localized synovial inflammation in patients with systemic lupus erythematosus affecting a single joint.
• Acute flare of ankylosing spondylitis involving peripheral joints when systemic therapy is unsuitable.

• Triamcinolone hexacetonide exerts its anti‑inflammatory effect by binding to intracellular glucocorticoid receptors. The drug‑receptor complex translocates to the nucleus, where it interacts with glucocorticoid response elements and suppresses transcription of pro‑inflammatory genes such as those encoding cytokines, chemokines, and adhesion molecules. It also up‑regulates anti‑inflammatory proteins, reduces leukocyte migration, and stabilizes lysosomal membranes, resulting in decreased synovial inflammation and joint swelling.

Adverse reactions to intra‑articular Hexatrione are generally related to its corticosteroid activity and the injection procedure.

Common

• Transient pain or swelling at the injection site that usually resolves within a few days.
• Localized bruising or bleeding under the skin, often noticeable as a small discoloration.
• Temporary increase in blood glucose levels in patients with diabetes, requiring monitoring.
• Mild warmth or redness around the injection site, indicative of a short‑term inflammatory response.

Serious

• Joint infection (septic arthritis) that may present with increasing pain, fever, and swelling, requiring urgent medical attention.
• Significant tendon rupture or ligament weakening in the treated joint, which can compromise joint stability.
• Systemic corticosteroid effects such as adrenal suppression, which are rare after a single intra‑articular dose but may occur with repeated use.
• Allergic reaction to the formulation, presenting as rash, urticaria, or itching at the injection site or elsewhere.

Before using Hexatrione, clinicians should evaluate patient history and consider specific safety considerations.

• Assess for active infections, especially joint or systemic infections, before injection.
• Use caution in patients with uncontrolled diabetes due to possible hyperglycemia.
• Avoid intra‑articular administration in joints with recent surgery or severe osteopenia.
• Screen for known hypersensitivity to triamcinolone or any formulation components.
• Monitor for signs of adrenal suppression when multiple injections are planned.
• Consider the risk of tendon or ligament weakening in elderly or physically active patients.

Hexatrione may interact with other medicines that affect corticosteroid activity, immune function, or increase the risk of infection, and clinicians should review concomitant therapies before administration.

Avoid

• Systemic immunosuppressants such as methotrexate, azathioprine, or biologic agents may increase overall immunosuppression and infection risk.
• Live attenuated vaccines should be avoided for at least four weeks after injection to ensure efficacy.

Use with caution

• Anticoagulants (warfarin, DOACs, heparin) may raise bleeding or hematoma risk at the injection site.
• Concurrent NSAIDs can increase gastrointestinal irritation and may mask early signs of joint infection.
• Patients on antidiabetic drugs should monitor glucose, as intra‑articular steroids can cause a temporary rise.